[ALLIANZ] YoY Quarter Result on 31-Dec-2021 [#4]

Stock
[ALLIANZ] ALLIANZ MALAYSIA BHD
Announcement Date
22-Feb-2022
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2021
Quarter
31-Dec-2021 [#4]
Profit Trend
QoQ- 34.32%
YoY- 7.39%
Quarter Report
Latest QR
Upcoming QR
ALLIANZ's Result
ALLIANZ's Financial Summary
View:
Show?
Quarter Result
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
Revenue 1,309,506 1,703,900 1,671,277 1,526,097 1,405,471 1,302,173 1,209,867 1.32%
PBT 239,364 267,482 193,025 186,854 188,158 127,837 126,385 11.22%
Tax -45,673 -101,144 -38,351 -42,826 -55,076 -27,797 -39,603 2.40%
NP 193,691 166,338 154,674 144,028 133,082 100,040 86,782 14.31%
-
NP to SH 193,691 166,338 154,674 144,028 133,082 100,040 86,782 14.31%
-
Tax Rate 19.08% 37.81% 19.87% 22.92% 29.27% 21.74% 31.34% -
Total Cost 1,115,815 1,537,562 1,516,603 1,382,069 1,272,389 1,202,133 1,123,085 -0.10%
-
Net Worth 5,139,751 4,219,436 4,140,538 4,031,296 3,669,934 3,322,561 3,120,801 8.66%
Dividend
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
Div 122,798 122,482 111,714 102,595 114,851 69,838 20,851 34.36%
Div Payout % 63.40% 73.63% 72.23% 71.23% 86.30% 69.81% 24.03% -
Equity
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
Net Worth 5,139,751 4,219,436 4,140,538 4,031,296 3,669,934 3,322,561 3,120,801 8.66%
NOSH 177,969 177,969 177,508 176,888 176,887 176,688 174,582 0.32%
Ratio Analysis
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
NP Margin 14.79% 9.76% 9.25% 9.44% 9.47% 7.68% 7.17% -
ROE 3.77% 3.94% 3.74% 3.57% 3.63% 3.01% 2.78% -
Per Share
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
RPS 735.80 959.88 942.49 862.74 795.43 745.82 696.27 0.92%
EPS 30.56 15.23 15.37 14.80 0.57 10.69 49.94 -7.85%
DPS 69.00 69.00 63.00 58.00 65.00 40.00 12.00 33.83%
NAPS 28.88 23.77 23.35 22.79 20.77 19.03 17.96 8.23%
Adjusted Per Share Value based on latest NOSH - 177,508
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
RPS 729.25 948.88 930.71 849.87 782.69 725.16 673.76 1.32%
EPS 107.86 92.63 86.14 80.21 74.11 55.71 48.33 14.30%
DPS 68.39 68.21 62.21 57.13 63.96 38.89 11.61 34.36%
NAPS 28.6227 23.4975 23.0582 22.4498 20.4374 18.503 17.3794 8.66%
Price Multiplier on Financial Quarter End Date
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
Date 29/12/23 30/12/22 31/12/21 31/12/20 31/12/19 31/12/18 29/12/17 -
Price 18.44 14.16 12.86 14.78 16.28 13.00 13.50 -
P/RPS 2.51 1.48 1.36 1.71 2.05 1.74 1.94 4.38%
P/EPS 16.94 15.11 14.74 18.15 21.62 22.69 27.03 -7.48%
EY 5.90 6.62 6.78 5.51 4.63 4.41 3.70 8.08%
DY 3.74 4.87 4.90 3.92 3.99 3.08 0.89 27.01%
P/NAPS 0.64 0.60 0.55 0.65 0.78 0.68 0.75 -2.60%
Price Multiplier on Announcement Date
31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 CAGR
Date 26/02/24 23/02/23 22/02/22 24/02/21 27/02/20 21/02/19 22/02/18 -
Price 18.56 13.88 12.66 13.76 15.70 14.00 13.10 -
P/RPS 2.52 1.45 1.34 1.59 1.97 1.88 1.88 5.00%
P/EPS 17.05 14.81 14.51 16.90 20.85 24.43 26.23 -6.92%
EY 5.86 6.75 6.89 5.92 4.80 4.09 3.81 7.43%
DY 3.72 4.97 4.98 4.22 4.14 2.86 0.92 26.20%
P/NAPS 0.64 0.58 0.54 0.60 0.76 0.74 0.73 -2.16%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment